|
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
Millennium | Media | Press Releases | 2003 | 2003-06-02
2003 2002 Millennium Announces Preliminary Phase I and Phase II Findings of VELCADE™ (bortezomib) for Injection in Studies of Non-Hodgkin's Lymphoma and Solid Tumors – Evidence of anti-tumor activity reported with VELCADE as a single agent and in combination with other therapies – Chicago, Ill., June 2, 2003 - Millennium Pharmaceuticals, Inc.
VELCADE Studied in...
|
|
|
Millennium | Media | Press Releases | 2003 | 2003-01-15
2003 2002 Millennium Initiates Phase II Clinical Trial With VELCADE™ (bortezomib) for Injection in Patients with Advanced Non-Small Cell Lung Cancer – Company-sponsored trial will evaluate VELCADE alone and in combination with Taxotere® – Cambridge, Mass., (January 15, 2003) - Millennium Pharmaceuticals, Inc.
The randomized, open-label study will assess...
|
|
|
Cancer: Breast Disorders: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
|
|
|
GPC-Biotech
- “The data presented at AACR indicate that satraplatin remains active in drug-resistant tumor cells pre-treated with other commonly used anticancer drugs,” said Marcel Rozencweig, M.D., Senior Vice President, Drug Development.- “These in vitro data support our plans to initiate additional clinical trials evaluating satraplatin in combination with a variety of other...
author: Form+Fakten, Maximilian Vollendorf
|
|
|
GPC-Biotech
Wilding.- “The favorable safety profile and clinical activity of satraplatin in several solid tumor types and the proven efficacy of TAXOTERE in various cancers make this a treatment regimen that has the potential to help many patients with cancer.” - “We are pleased to have Dr.
Actual results could differ materially depending on a number of factors, including...
author: Form+Fakten, Maximilian Vollendorf
|
|
|
GPC-Biotech
Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements Overview Strategy Executive Committee Supervisory Board Locations Overview Satraplatin Monoclonal Antibody Cdk Inhibitors Research Programs Growing the Pipeline Alliances Stock Key Figures Financial...
author: Form+Fakten, Maximilian Vollendorf
|
|
|
GPC-Biotech
Home Deutsch About the Company Anticancer Programs Technologies Investor Relations News &-Media Careers Calendar Contact/- Imprint Sitemap Search Glossary Forward Look-ing Statements Overview Strategy Executive Committee Supervisory Board Locations Overview Satraplatin Monoclonal Antibody Cdk Inhibitors Research Programs Growing the Pipeline Alliances Stock Key Figures Financial...
author: Form+Fakten, Maximilian Vollendorf
|
|
|
Welcome to Genta Incorporated
- - Genasense ® is a drug that inhibits the production of a protein known as Bcl-2.
This process is known as programmed cell death or apoptosis.
Genta's clinical trials programs focus on pretreating cancer patients with Genasense prior to the administration of anticancer therapy with the intention of potentiating the cancer-killing effects of treatment.
Genta is...
|
